Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil

Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas Hunt, Nicholas S Hill, Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas Hunt, Nicholas S Hill

Abstract

A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hypertension via nebulized Tyvaso® inhalation solution. LTI-101 was a phase 1, placebo-controlled, double-blind, randomized, single-center study that evaluated the ascending single-dose pharmacokinetics of LIQ861 in healthy subjects. Six sequential, escalating doses (25, 50, 75, 100, 125, and 150 mcg) were studied to investigate treprostinil exposure from LIQ861 inhalation. Subjects (n = 57) were randomly assigned in a 3:1 ratio to receive a single dose of either LIQ861 (n = 43) or placebo (n = 14); 56 subjects completed all protocol-defined assessments. Following single-dose administration, treprostinil exposure from LIQ861 increased proportionally across the dose range studied, and the pharmacokinetics profile of treprostinil administered as LIQ861 was similar to prior reports of inhaled treprostinil. All doses of LIQ861 were generally well-tolerated with no deaths, serious adverse events, or dose-limiting toxicities. The most frequently reported treatment-emergent adverse events related to study drug administration were coughing and throat irritation, which are common to dry-powder formulations. Treatment-related treatment-emergent adverse events were reported more frequently at higher dose levels; however, all were assessed as mild in severity. We conclude that the pharmacokinetics profile of treprostinil using a dry-powder inhaled formulation increased in proportion to dose as anticipated and was similar to earlier reports of inhaled, nebulized treprostinil (Tyvaso®). Based on these results, a phase 3 study (INSPIRE; Clinicaltrials.gov Identifier NCT03399604) evaluating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension was initiated.

Keywords: inhaled prostacyclin; pharmacokinetics; pulmonary arterial hypertension.

© The Author(s) 2020.

Figures

Fig. 1.
Fig. 1.
LIQ861 particles and dry-powder inhaler.
Fig. 2.
Fig. 2.
Mean plasma treprostinil concentration over time.

References

    1. Ataya A, Cope J, Alnuaimat H. A review of targeted pulmonary arterial hypertension-specific pharmacotherapy. J Clin Med 2016; 5: 114.
    1. Badlam JB, Bull TM. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis 2017; 8: 47–64.
    1. Barnes H, Yeoh HL, Fothergill T, et al. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev 2019; 5: CD012785.
    1. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–75.
    1. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–1932.
    1. Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med 2017; 11: 491–503.
    1. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev 2016; 25: 418–430.
    1. Galiè N, Humbert M, Vachiery JL, et al.; ESC Scientific Document Group. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: Association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
    1. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891–901.
    1. Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL registry. J Heart Lung Transplant 2013; 32: 1114–1122.
    1. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012; 21: 8–18.
    1. McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013; 34: 825–840.
    1. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010; 137: 376–387.
    1. United Therapeutics Corp. Remodulin (package insert). Durham, NC: United Therapeutics Corp, 2018.
    1. Actelion Pharmaceuticals US, Inc. Veletri (package insert) South San Francisco, CA: Actelion Pharmaceuticals US, Inc., 2018.
    1. United Therapeutics Corp. Tyvaso (package insert). Durham, NC: United Therapeutics Corp, 2017.
    1. Actelion Pharmaceuticals US, Inc. Ventavis (package insert). South San Francisco, CA: Actelion Pharmaceuticals US, Inc, 2017.
    1. United Therapeutics Corp. Orenitram (package insert). Durham, NC: United Therapeutics Corp, 2019.
    1. Actelion Pharmaceuticals US, Inc. Uptravi (package insert). South San Francisco, CA: Actelion Pharmaceuticals US, Inc, 2019.
    1. Hohsfield R, Archer-Chicko C, Housten T, et al. Pulmonary arterial hypertension emergency complications and evaluation: practical guide for the advanced practice registered nurses in the emergency department. Adv Emerg Nurs J 2018; 40: 246–259.
    1. GlaxoSmithKline. Flolan (Package insert). Zebulon, NC: GlaxoSmithKline, 2018.
    1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–1436.
    1. Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ 2017; 7: 598–608.
    1. LeVarge BL. Prostanoid therapies in the management of pulmonary arterial hypertension. Ther Clin Risk Manag 2015; 11: 535–547.
    1. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9–21.
    1. Picken C, Fragkos KC, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and Meta-analysis. J Clin Med 2019; 8: 481.
    1. Simonneau G, Barst RJ, Galiè N, et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
    1. Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care 2015; 60: 794–802.
    1. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 56S–61S.
    1. El Yafawi R, Wirth JA. What is the role of oral prostacyclin pathway medications in pulmonary arterial hypertension management? Curr Hypertens Rep 2017; 19: 97.
    1. Maynor BW. 21st century particle engineering: particle design, manufacture and scale-up of PRINT® technology. Respir Drug Deliv 2018; 1: 211–220.
    1. Mack P, Tully J, Herlihy KP, et al. Formulation and in vivo evaluation of treprostinil dry powder for inhalation, fabricated using the PRINT® particle technology. Respir Drug Deliv 2014; 2: 473–476.
    1. Garcia A, Mack P, Williams S, et al. Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv 2012; 2012: 941243.
    1. Roscigno R, Vaughn T, Wargin W, et al. Phase 1 safety and pharmacokinetic study of inhaled LIQ861: a new dry powder formulation of treprostinil In: Presented at: PHA’s international pulmonary hypertension conference, Orlando, FL, 28 June–1 July 2018.
    1. Moein MM, El Beqqali A, Abdel-Rehim M. Bioanalytical method development and validation: critical concepts and strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1043: 3–11.
    1. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17: 1278–1283.
    1. Hummel J, McKendrick S, Brindley C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009; 8: 38–49.
    1. Kumar P, Thudium E, Laliberte K, et al. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet 2016; 55: 1495–1505.
    1. Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 2012; 6: 19–28.
    1. Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev 2015; 24: 630–641.
    1. Sitbon O, Channick R, Chin KM, et al.; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.
    1. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 2011; 30: 1327–1333.
    1. Parikh KS, Rajagopal S, Fortin T, et al. Safety and tolerability of high-dose inhaled treprostinil in pulmonary hypertension. J Cardiovasc Pharmacol 2016; 67: 322–325.
    1. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21: 824–832.
    1. . Investigation of the safety and pharmacology of dry-powder inhalation of treprostinil (INSPIRE), (2018, accessed 6 August 2019).
    1. Hill NS, Feldman JP, Sahay S, et al. INSPIRE: a phase 3 open-label, multicenter study to evaluate the safety and tolerability of LIQ861 in pulmonary arterial hypertension (PAH). J Heart Lung Transplant 2019; 38: S11.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner